ASAlicia Santos

Alicia Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alicia Santos has a total of 281 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Patient‐reported measures in hypothalamic–pituitary diseases

    by Susan M. Webb, Alicia Santos, Queralt Asla, Rebeca Marín, Anna Aulinas

    Modern medicine centres its focus on the central stakeholder, the patient, to deliver a more patient‐centred and holistic care and improve quality of care, emphasizing the importance of communication between healthcare providers and patients. To learn how the patient experiences and evaluates outcome of any health intervention, different tools have been developed, known as PREMs (Patient‐Reported Experience Measures) and PROMs (Patient‐Reported Outcome Measures). PREMs reflect the patient's personal experience when being cared for, like whether the professionals explained things clearly, or if they felt they were treated with dignity and are indicators of the care process, i.e., communication, access, environment, coordination, etc. and are used to improve service quality and patient‐centredness. PROMs are linked to clinical outcomes and reflect the patient's feelings about their health and may include, among others, pain scales, mobility questionnaires or psychosocial inventories. They are used to assess the effectiveness of treatment, like before and after surgery and focus on symptoms, functioning, and health‐related quality of life (HRQoL). This review summarizes available information on PREMs, PROMs and HRQoL in patients with hypothalamic–pituitary diseases, specifically, Cushing disease, acromegaly, prolactinoma, non‐functioning pituitary adenoma, hypopituitarism (including adult growth hormone and arginine vasopressin deficiencies) and craniopharyngioma. On the whole, hormone dysfunction and mass control after medical or surgical treatment improves HRQoL, but it often remains worse than in healthy control population. Additionally, it is important to ask the patients what affects them most, since the identification and relevance of complaints and experiences are often different among pituitary patients and healthcare providers.

  • Open Access

    Prevalence, risk factors and management of bone complications in Cushing's syndrome across Europe. Data from the European Registry on Cushing's syndrome (ERCUSYN)

    by Aleksandra Zdrojowy-Wełna, Claudia Amaral, Marta Araujo-Castro, Nienke Biermasz, Marek Bolanowski, Jens Bollerslev, Thierry Brue, Davide Carvalho, Frederic Castinetti, Filippo Ceccato, et al.


  • Open Access

    Quality of life and psychological status in people with acromegaly in relation to disease-related facial changes

    by Maria Antonia Martínez-Momblán, Sergio Alonso-Fernández, Montserrat Marques-Pamies, Isabel Salinas, Federico Vázquez, Berta Soldevila, Diego Asensio-Wandosell, Raquel Ciriza, Alicia Santos, Elena Valassi, et al.

    The diagnosis of acromegaly is often delayed, leading to facial disfigurements that persist despite endocrine cure. We aimed to study the relationship between facial modifications, quality of life (QoL) and psychological status in patients with acromegaly. Methods: Sixty-five patients in remission or with hormonal disease control participated (29 women and 36 men; mean age 57.4 ± 13.5 years). The following variables were assessed: i) sex; ii) QoL by AcroQoL; iii) anxiety level with the STAI questionnaire; iv) self-esteem by the Rosenberg scale; and v) facial acromegaly phenotypical changes evaluated from face photographs by eight experienced endocrinologists using a Likert scale. Results: The global AcroQoL score for the whole cohort showed mid-range values, with higher median values for men (72.3 vs 56.6, P = 0.022) mostly dependent on the physical domain, which was higher for men (59.0 vs 34.9, P = 0.006), rather than the psychological domain (65.7 vs 54.5, P = 0.069). Anxiety scores were also higher for women (7.3 vs 5.9, P = 0.009). Self-esteem state was high (2.7 ± 0.6 for a maximal value of 3) for the whole cohort without sex differences. A higher difference in the global phenotypic facial acromegaly features score from baseline and post-diagnosis was associated with a lower value on QoL mostly in women (−14.38 95% CI −5.25 to −23.52; P-value = 0.005), with less effect in men (−6.31 95% CI 0.61 to −13.22; P-value = 0.070). Conclusion: In controlled acromegaly, QoL is relatively preserved in both genders, although men have higher general and physical domain scores and lower anxiety status. Facial changes intensity negatively impacted QoL mostly in women.


  • Open Access

    Cushing's syndrome in the elderly: data from the European Registry on Cushing's syndrome

    by Vincent Amodru, Amandine Ferriere, Antoine Tabarin, Frederic Castinetti, Stylianos Tsagarakis, Miklos Toth, Richard A Feelders, Susan M Webb, Martin Reincke, Romana Netea-Maier, et al.

    Objective: To evaluate whether age-related differences exist in clinical characteristics, diagnostic approach, and management strategies in patients with Cushing's syndrome (CS) included in the European Registry on Cushing's Syndrome (ERCUSYN).Design: Cohort study.Methods: We analyzed 1791 patients with CS, of whom 1234 (69%) had pituitary-dependent CS (PIT-CS), 450 (25%) adrenal-dependent CS (ADR-CS), and 107 (6%) had an ectopic source (ECT-CS). According to the WHO criteria, 1616 patients (90.2%) were classified as younger (<65 years old) and 175 (9.8%) as older (≥65 years old).Results: Older patients were more frequently males and had a lower Body Mass Index (BMI) and waist circumference when compared with the younger. Older patients also had a lower prevalence of skin alterations, depression, hair loss, hirsutism, and reduced libido, but a higher prevalence of muscle weakness, diabetes, hypertension, cardiovascular disease, venous thromboembolism, and bone fractures than younger patients, regardless of sex (P < .01 for all comparisons). Measurement of urinary free cortisol supported the diagnosis of CS less frequently in older patients when compared with the younger (P < .05). An extrasellar macroadenoma (macrocorticotropinoma with extrasellar extension) was more common in older PIT-CS patients than in the younger (P < .01). Older PIT-CS patients more frequently received cortisol-lowering medications and radiotherapy as a first-line treatment, whereas surgery was the preferred approach in the younger (P < .01 for all comparisons). When transsphenoidal surgery was performed, the remission rate was lower in the elderly when compared with their younger counterpart (P < .05).Conclusions: Older CS patients lack several typical symptoms of hypercortisolism, present with more comorbidities regardless of sex, and are more often conservatively treated.


  • Open Access

    Attachment-Based Compassion Therapy for Reducing Anxiety and Depression in Fibromyalgia

    by Alicia Santos, Iris Crespo, Adrián Pérez-Aranda, María Beltrán-Ruiz, Marta Puebla-Guedea, Javier García-Campayo

    Fibromyalgia patients often experience anxiety and depressive symptoms; however, validated interventions show only limited efficacy. This pilot study analyzed the effects of a 16-session version of attachment-based compassion therapy (ABCT-16) for improving anxiety and depressive symptomatology, as well as self-compassion and decentering, in 11 fibromyalgia patients. Scales were assessed at four time points: baseline, after sessions 8 and 16, and 3.5 months after the completion of the program. Significant improvements were found in all outcomes after the program, and most remained significant in the follow-up assessment. Our preliminary results suggest that ABCT-16 can be effective for improving anxiety and depressive symptomatology in fibromyalgia patients. Nonetheless, further studies with larger samples and control groups are necessary to confirm these results.


  • Psychological complications of Cushing's syndrome

    by Alicia Santos, Susan M. Webb, Eugenia Resmini

    Purpose of review: The aim of this article is to review and discuss recent evidence of psychological complications in Cushing's syndrome. Recent findings: Recent research has described the presence of depression, anxiety, posttraumatic stress disorder, mania, bipolar disorder and psychotic symptoms in patients with Cushing's syndrome. Furthermore, the perspective of patients’ partners has also been emphasized. Summary: Recent literature highlights the importance of screening for psychological alterations in Cushing's syndrome, as these alterations can be present in many patients, having a high impact in daily life. Depression is a very common symptom, although in rare cases, patients can also present mania or psychosis. Some studies highlight the importance of screening for organic disease (including Cushing's syndrome) in patients with unexpected or first onset psychiatric symptoms. Finally, the perspective of the patients’ partners makes it clear that the partners can also suffer due to the disease of the patient. Intervention programmes involving patient's partners could be helpful to improve both patient and partner wellbeing.


  • Open Access

    Quality of Life in Cushing's disease: A long term issue?

    by Susan M. Webb, Alicia Santos, Eugenia Resmini, Maria-Antonia Martínez-Momblán, Luciana Martel, Elena Valassi


  • Psychopathology in Cushing's disease and acromegaly

    by Alicia Santos, Eugenia Resmini, Iris Crespo, Elena Valassi, Ma Antonia Martinez, Susan M Webb

    Introduction: Cushing’s disease (CD) and acromegaly, despite their different specific symptoms, often present psychopathology (mainly depression and anxiety) even after hormonal normalization. However, their psychopathological profiles may be different. The aim of this study was to analyse the psychopathological profile in successfully treated Acromegaly and CD, and to compare both diseases. Current hormonal evaluation and time since endocrine control will also be analysed. Methods: Twenty-one patients in remission of CD, twenty patients with controlled acromegaly for at least one year and 41 matched controls for age, sex and education years were included in the study. They completed SCL-90R, Beck Depression Inventory II (BDI-II), State- Trait Anxiety Inventory (STAI) and underwent endocrine evaluation. Results: Patients with CD and acromegaly presented more psychopathology than controls in most of the areas evaluated (Depression, Anxiety, Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Hostility, Paranoid Ideation, Psychoticism, Global Severity Index, Positive Symptom Distress Index and Positive Symptoms Total PPP=0.036) and Global Severity Index (P=0.036) CS patients had higher scores, while in acromegaly scores were higher for Positive Symptoms Total (P=0.001). In CD (excluding those taking hydrocortisone), correlations were found between psychopathology and both morning cortisol (STAI-State: P=0.027, R=0.521, STAI-Trait: P=0.037, R=0.495, Depression P=0.035, R=0.513, Hostility: P=0.041, R=0.500) and 24 hour urinary free cortisol (STAI-Trait: P=0.038, R=0.521, Depression: P=0.038, R=0.539, Hostility: P=0.007, R=0.663, Psychoticism: P=0.024, R=0.578, Global Severity Index: P=0.012, R=0.629, Positive Symptoms Total: P=0.040, R=0.534). No correlations were found between psychopathology and IGF1 or GH in acromegaly. No correlations were found in normal controls between psychopathology and hormonal parameters. Psychopathology did not correlate with time since endocrine control. Conclusions: After at least 1 year of cure, patients with CD and acromegaly score higher on psychopathology than controls. Current cortisol evaluation, despite being within normal values, correlated with psychopathology in CD, but not in controls. Despite some similarities, CD showed more somatizations, paranoid ideation and higher severity of psychopathological symptoms, while acromegalic patients reported a higher number of psychopathological symptoms.

  • Preoperative medical treatment in Cushing’s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN

    by Elena Valassi, Holger Franz, Thierry Brue, Richard A Feelders, Romana Netea-Maier, Stylianos Tsagarakis, Susan M Webb, Maria Yaneva, Martin Reincke, Michael Droste, et al.

    Background: Surgery is the definitive treatment of Cushing’s syndrome (CS) but medications may also be used as a first-line therapy. Whether preoperative medical treatment (PMT) affects postoperative outcome remains controversial. Objective: (1) Evaluate how frequently PMT is given to CS patients across Europe; (2) examine differences in preoperative characteristics of patients who receive PMT and those who undergo primary surgery and (3) determine if PMT influences postoperative outcome in pituitary-dependent CS (PIT-CS). Patients and methods: 1143 CS patients entered into the ERCUSYN database from 57 centers in 26 countries. Sixty-nine percent had PIT-CS, 25% adrenal-dependent CS (ADR-CS), 5% CS from an ectopic source (ECT-CS) and 1% were classified as having CS from other causes (OTH-CS). Results: Twenty per cent of patients took PMT. ECT-CS and PIT-CS were more likely to receive PMT compared to ADR-CS (P < 0.001). Most commonly used drugs were ketoconazole (62%), metyrapone (16%) and a combination of both (12%). Median (interquartile range) duration of PMT was 109 (98) days. PIT-CS patients treated with PMT had more severe clinical features at diagnosis and poorer quality of life compared to those undergoing primary surgery (SX) (P < 0.05). Within 7 days of surgery, PIT-CS patients treated with PMT were more likely to have normal cortisol (P < 0.01) and a lower remission rate (P < 0.01). Within 6 months of surgery, no differences in morbidity or remission rates were observed between SX and PMT groups. Conclusions: PMT may confound the interpretation of immediate postoperative outcome. Follow-up is recommended to definitely evaluate surgical results.


  • Worse Health‐Related Quality of Life at long‐term follow‐up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN

    by Elena Valassi, Richard Feelders, Dominique Maiter, Philippe Chanson, Maria Yaneva, Martin Reincke, Michal Krsek, Miklós Tóth, Susan M. Webb, Alicia Santos, et al.

    Summary: Objective: Hypercortisolism in Cushing's syndrome (CS) is associated with impaired health‐related quality of life (HRQoL), which may persist despite remission. We used the data entered into the European Registry on Cushing's syndrome (ERCUSYN) to evaluate if patients with CS of pituitary origin (PIT‐CS) have worse HRQoL, both before and after treatment than patients with adrenal causes (ADR‐CS).Methods: Data from 595 patients (492 women; 83%) who completed the CushingQoL and/or EQ‐5D questionnaires at baseline and/or following treatment were analysed.Results: At baseline, HRQoL did not differ between PIT‐CS (n = 293) and ADR‐CS (n = 120) on both EuroQoL and CushingQoL. Total CushingQoL score in PIT‐CS and ADR‐CS was 41 ± 18 and 44 ± 20, respectively (P = .7). At long‐time follow‐up (>1 year after treatment) total CushingQoL score was however lower in PIT‐CS than ADR‐CS (56 ± 20 vs 62 ± 23; P = .045). In a regression analysis, after adjustment for baseline age, gender, remission status, duration of active CS, glucocorticoid dependency and follow‐up time, no association was observed between aetiology and HRQoL. Remission was associated with better total CushingQoL score (P < .001), and older age at diagnosis with worse total score (P = .01). Depression at diagnosis was associated with worse total CushingQoL score at the last follow‐up (P < .001).Conclusion: PIT‐CS patients had poorer HRQoL than ADR‐CS at long‐term follow‐up, despite similar baseline scoring. After adjusting for remission status, no interaetiology differences in HRQoL scoring were found. Age and presence of depression at diagnosis of CS may be potential predictors of worse HRQoL regardless of CS aetiology.